绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02480 绿竹生物-B

未开盘 11-02 15:34:53

15.300

-0.100

-0.65%

最高15.300	最低15.300	成交量200.00
今开15.300	昨收15.400	日振幅0.00%
总市值30.45亿	流通市值30.45亿	总股本1.99亿
成交额3,060	换手率0.00%	流通股本1.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02480","market":"HK","secType":"STK","nameCN":"绿竹生物-B","latestPrice":15.3,"timestamp":1793604893965,"preClose":15.4,"halted":0,"volume":200,"delay":0,"changeRate":-0.0064935064935064705,"floatShares":199000000,"shares":199000000,"eps":-0.75,"marketStatus":"未开盘","change":-0.1,"latestTime":"11-02 15:34:53","open":15.3,"high":15.3,"low":15.3,"amount":3060,"amplitude":0,"askPrice":15.4,"askSize":200,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.780055,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793669400000},"marketStatusCode":0,"adr":0,"listingDate":1683475200000,"exchange":"SEHK","adjPreClose":15.4,"openAndCloseTimeList":[[1793583000000,1793592000000],[1793595600000,1793606400000]],"volumeRatio":0.999999,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02480/tweets","defaultTab":"tweets","newsList":[{"id":"1198163221","title":"绿竹生物-B更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1198163221","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198163221?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:20","pubTimestamp":1793622053,"startTime":"0","endTime":"0","summary":"北京绿竹生物技术股份有限公司于2026年11月2日公布了截至2026年10月31日的股份变动月报表。报告期内，公司法定/注册股本为2.02亿元，与上月末持平。期末已发行普通股198,913,232股，库存股3,535,800股，合计202,449,032股，较上月底没有增减变动。月报显示，截至10月31日，绿竹生物-B股本结构保持稳定，持续符合香港联合交易所有限公司的最低公众持股量要求。公司同时确认已遵守相关上市规则及法律规定。本次公告由公司秘书刘斯宇签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115817389","title":"绿竹生物-B（02480）披露合计交易超5%：认购2,765万元理财产品并集中赎回 招行理财余额2,930万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115817389","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115817389?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:20","pubTimestamp":1793622051,"startTime":"0","endTime":"0","summary":"11月2日，北京时间——绿竹生物-B公告称，公司及其子公司在2025年9月3日至公告日期间，与招商银行股份有限公司及中国民生银行股份有限公司分别进行多笔理财产品的认购及出售。经合并计算，相关交易最高适用百分比率均超过5%但低于25%，构成香港联交所上市规则第十四章所规定的须予披露交易。截至公告日期，招商银行理财产品的本金余额为人民币2,930万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198458966","title":"绿竹生物-B（02480）宣布更换香港法律程序文件接收人","url":"https://stock-news.laohu8.com/highlight/detail?id=1198458966","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198458966?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:36","pubTimestamp":1793003781,"startTime":"0","endTime":"0","summary":"北京绿竹生物技术股份有限公司10月26日发布公告称，公司董事会已收到赖浩恩女士提交的辞呈，其将自2026年10月26日起辞去公司根据香港法例第622章《公司条例》第16部及香港联合交易所有限公司证券上市规则第19A.13条所规定的获授权代表职务，即在香港接收法律程序文件及通知书的代理人。赖浩恩女士确认，其与董事会并无意见分歧，且无其他事项需提请香港联合交易所有限公司及/或公司股东注意。董事会对其任职期间的贡献表示感谢。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678168273","title":"绿竹生物-B(02480.HK)：黄慧儿获委任为法律程序文件接收人","url":"https://stock-news.laohu8.com/highlight/detail?id=2678168273","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678168273?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:31","pubTimestamp":1793003504,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02480","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121890815","title":"绿竹生物-B（02480）获批在华开展重组RSV疫苗临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1121890815","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121890815?lang=zh_cn&edition=full","pubTime":"2026-10-12 19:06","pubTimestamp":1791803183,"startTime":"0","endTime":"0","summary":"2026年10月12日，北京绿竹生物技术股份有限公司发布自愿性公告称，公司自主研发的重组呼吸道合胞病毒疫苗已获国家药品监督管理局批准，可在中国开展临床试验。公司指出，当前中国尚无RSV特异性治疗药物，临床主要依赖对症支持治疗，市场对RSV疫苗存在迫切需求。公司同时提醒投资者，依据香港联合交易所有限公司证券上市规则第18A.05条的相关要求，重组RSV疫苗最终能否成功开发及商业化尚存在不确定性，投资者在买卖公司股份时应保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674741498","title":"绿竹生物-B：重组RSV疫苗在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674741498","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674741498?lang=zh_cn&edition=full","pubTime":"2026-10-12 19:03","pubTimestamp":1791802980,"startTime":"0","endTime":"0","summary":"南财智讯10月12日电，绿竹生物-B（02480.HK）发布自愿公告，公司开发的重组呼吸道合胞病毒（RSV）疫苗已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品是公司自主研发的预防由RSV引起的下呼吸道疾病的重组蛋白疫苗候选产品，属于液体剂型含铝佐剂疫苗，采用RSV融合前F蛋白抗原。本次临床试验获批为公司后续重组蛋白疫苗候选品种的开发工作奠定了坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610123892811551.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610123892811551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","BK1161","02480","IBBQ","IBBJ","PSYK","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121917220","title":"绿竹生物-B发布9月股份变动月报表 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1121917220","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121917220?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:36","pubTimestamp":1791189417,"startTime":"0","endTime":"0","summary":"绿竹生物-B于2026年10月5日发布的截至2026年9月30日的月度证券变动报告显示，报告期内公司已发行及注册股本均未发生变动。据公告，本期末公司普通股已发行股本总数为202,449,032股，其中已发行股份为198,913,232股，库藏股份为3,535,800股，总股本与上月底持平。公司表示，已遵守香港联交所《上市规则》及相关法律法规，所有涉及公司股份的发行、回购与持有事项均符合法律和监管要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129712111","title":"北京绿竹生物技术股份：强化股份奖励计划合规限制，完善2025年度报告关键信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1129712111","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129712111?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:23","pubTimestamp":1790252634,"startTime":"0","endTime":"0","summary":"2026年9月24日，北京绿竹生物技术股份有限公司发布补充公告，就拟于2026年4月23日刊发的截至2025年12月31日止年度的年度报告提供进一步说明。公告主要围绕2025年度股份奖励计划的前期批准事项及「股票挂钩协议信息」的修订，强调了本公司在管理及决策机制上对合规性和透明度的重视，并说明相关补充资料不会影响2025年度报告所载的其他信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"北京绿竹生物技术股份：强化股份奖励计划合规限制，完善2025年度报告关键信息","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136229956","title":"绿竹生物-B 2026年8月无新增发行及股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1136229956","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136229956?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:57","pubTimestamp":1788339436,"startTime":"0","endTime":"0","summary":"北京绿竹生物技术股份有限公司于2026年9月2日披露的2026年8月股份变动月报表显示，截至2026年8月31日，公司股本结构保持稳定，未有新增发行或股份变动。报告显示当月无股份回购、注销或股份期权、股权激励计划及可换股票据、认股权证等方面的变动。公司在公告中确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137355516","title":"绿竹生物-B2026年中期财报：其他收入约676.20万元，同比增长39.4%，非公认会计准则口径净亏损约6,162.20万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137355516","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137355516?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:38","pubTimestamp":1787733500,"startTime":"0","endTime":"0","summary":"根据最新公告，绿竹生物-B在2026年上半年取得其他收入约676.20万元，同比增长39.4%。公司同期经非公认会计准则口径测算的净亏损约6,162.20万元，与去年同期相比下降20.6%，亏损幅度有所收窄。公告显示，绿竹生物-B在本期行政开支约2,828.90万元，同比增长9.6%；研发费用约3,033.10万元，同比降低39.7%。公司表示，研发投入的变化主要系在研产品处于不同临床阶段导向所致。经营活动所用现金净额为4,560.80万元，相较于上年同期的7,528.50万元有所改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"绿竹生物-B2026年中期财报：其他收入约676.20万元，同比增长39.4%，非公认会计准则口径净亏损约6,162.20万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796287","title":"绿竹生物-B(02480.HK)公布中期业绩 净亏损6162.2万元 同比减少20.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796287","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662796287?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:34","pubTimestamp":1787733241,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121927689","title":"绿竹生物-B（02480）计划8月26日审议2026年中期业绩及派息议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1121927689","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121927689?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:46","pubTimestamp":1786697191,"startTime":"0","endTime":"0","summary":"绿竹生物-B（02480）8月14日公告称，公司董事会拟于2026年8月26日（星期三）召开会议，届时将审议并批准本集团截至2026年6月30日止六个月的未经审计合并中期业绩，并讨论是否派发中期股息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161296280","title":"绿竹生物-B：彭玲减持，好仓比例降至5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161296280","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161296280?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:13","pubTimestamp":1786525985,"startTime":"0","endTime":"0","summary":"彭玲于2026年1月7日以每股均价23.0000港元卖出绿竹生物-B股份5.00万股，涉资约115.00万港元。彭玲此次减持前持有绿竹生物-B好仓1175.97万股，占比5.81%；减持后持股量为1170.97万股，好仓比例降至5.78%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658842672","title":"绿竹生物-B(02480.HK)于Nature Communications发表LZ901 III期临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2658842672","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658842672?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:29","pubTimestamp":1786271377,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181566683","title":"绿竹生物-B（02480）核心产品LZ901Ⅲ期临床数据发表于《Nature Communications》 总体保护效力91.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181566683","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181566683?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:25","pubTimestamp":1786271141,"startTime":"0","endTime":"0","summary":"北京绿竹生物技术股份有限公司8月9日发布自愿性公告称，其核心产品、在研重组带状疱疹疫苗LZ901的中国Ⅲ期临床试验结果已于2026年8月7日发表于国际期刊《Nature Communications》。本次Ⅲ期临床为多中心、随机、双盲、安慰剂对照研究，用于评估LZ901在40岁及以上成人中预防带状疱疹的有效性及安全性。根据香港联合交易所有限公司证券上市规则第18A.05条，公司无法保证LZ901最终能够成功获得批准并实现商业化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131409078","title":"绿竹生物-B发布7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1131409078","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131409078?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:41","pubTimestamp":1785832914,"startTime":"0","endTime":"0","summary":"2026年8月4日，北京绿竹生物技术股份有限公司披露了截至2026年7月31日的股份变动月报。报告期为2026年7月1日至7月31日。报告显示，公司的法定（注册）股本在期内未发生任何变动，依旧为人民币202,449,032元。公司确认，截至2026年7月31日，已经满足适用的公众持股量要求。本次公告由公司秘书刘斯宇签署。公司同时表示，所有已发行的股份变动均严格遵守香港联交所《上市规则》及相关法律法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100993086","title":"绿竹生物-B公布6月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1100993086","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100993086?lang=zh_cn&edition=full","pubTime":"2026-07-03 12:16","pubTimestamp":1783052176,"startTime":"0","endTime":"0","summary":"北京绿竹生物技术股份有限公司于2026年7月3日披露6月股份变动月报，报告期为截至2026年6月30日。公告显示，公司本月期间并无新增发行、回购或注销股份，股本结构保持稳定。根据公告，绿竹生物-B于报告期末普通股H股的法定/注册股本为人民币2.02亿元，与上个月持平。其中，已发行股份数量198,913,232股，库存股份数目3,535,800股，合计202,449,032股，较上月同样无变化。公司确认已符合截至本月末的适用公众持股量要求。本次月报由公司秘书刘斯宇签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189031804","title":"绿竹生物-B5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1189031804","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189031804?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:47","pubTimestamp":1780390041,"startTime":"0","endTime":"0","summary":"绿竹生物-B于2026年6月2日发布2026年5月31日止当月证券变动月报。公告显示，公司法定/注册股本与已发行股本在本月无变化，均保持在202,449,032股，面值每股人民币1元。截至2026年5月31日，绿竹生物-B普通股H股的已发行股份数量为198,913,232股，库存股份数量为3,535,800股，合计股本总数为202,449,032股，与上月底持平。报告期内无新增发行、购回、注销或库藏股份变动。本月内未发生涉及股份期权、股权激励或可转债的变动事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100400703","title":"绿竹生物-B拟回购不超10%已发行H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1100400703","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100400703?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:51","pubTimestamp":1779112297,"startTime":"0","endTime":"0","summary":"绿竹生物-B公告，将于2026年6月12日召开股东大会，审议并酌情批准授予董事股份购回授权。根据公告，该公司计划回购不超过截止股东大会通告日已发行H股总数10%的股份，即最多回购19,891,323股H股。公司称，回购所涉资金将遵循相关法规与公司章程，确保合法来源。董事会认为，此举旨在维护股东权益，优化公司资本结构，提高每股盈利水平，符合公司及其股东的整体最佳利益。公司提示，持有库存股份的投资者须就所持库存股份放弃该次表决权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"绿竹生物-B拟回购不超10%已发行H股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02480"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518571320","title":"绿竹生物-B03月11日主力净流入19万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2518571320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518571320?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:16","pubTimestamp":1741680990,"startTime":"0","endTime":"0","summary":"03月11日, 绿竹生物-B股价涨6.58%，报收24.30元，成交金额102万元，换手率0.02%，振幅6.14%，量比32.87。绿竹生物-B今日主力资金净流入19万元，上一交易日主力净流出0万元。该股近5个交易日上涨15.99%，主力资金累计净流入19万元；近20日主力资金累计净流入19万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165944abf609cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165944abf609cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://luzhubiotech.com","stockEarnings":[{"period":"1week","weight":-0.0065},{"period":"1month","weight":0.1418},{"period":"3month","weight":0.0929},{"period":"6month","weight":-0.3336},{"period":"1year","weight":-0.2756},{"period":"ytd","weight":-0.3517}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0951},{"period":"6month","weight":-0.1076},{"period":"1year","weight":-0.097},{"period":"ytd","weight":-0.0873}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京绿竹生物技术股份有限公司是一家主要从事疫苗及治疗性生物制剂的研究、开发及生产的中国公司。该公司还从事开发创新型人用疫苗及治疗性生物制剂，以预防及控制传染病以及治疗癌症及自身免疫性疾病。该公司的产品包括临床阶段的在研产品，以及临床前阶段的在研产品。核心产品LZ901，主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司主要在国内市场开展其业务","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.015264},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.050755},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.053698},{"month":4,"riseRate":0.666667,"avgChangeRate":0.180538},{"month":5,"riseRate":0,"avgChangeRate":-0.1833},{"month":6,"riseRate":0.75,"avgChangeRate":0.061327},{"month":7,"riseRate":0.5,"avgChangeRate":-0.008037},{"month":8,"riseRate":0.5,"avgChangeRate":0.048602},{"month":9,"riseRate":0.5,"avgChangeRate":-0.011714},{"month":10,"riseRate":0.5,"avgChangeRate":0.002116},{"month":11,"riseRate":0.25,"avgChangeRate":-0.011762},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.018225}],"exchange":"SEHK","name":"绿竹生物-B","nameEN":"LUZHU BIOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供绿竹生物-B(02480)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"绿竹生物-B,02480,绿竹生物-B股票,绿竹生物-B股票老虎,绿竹生物-B股票老虎国际,绿竹生物-B行情,绿竹生物-B股票行情,绿竹生物-B股价,绿竹生物-B股市,绿竹生物-B股票价格,绿竹生物-B股票交易,绿竹生物-B股票购买,绿竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供绿竹生物-B(02480)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}